secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2023-04-24T23:59:59+00:00
Accession:  0001171843-23-002460
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Pharmaceuticals regains Nasdaq minimum bid price compliance
------------------------------------------------------------------

- Received Nasdaq deficiency notice on Oct 25, 2022 for bid price below $1.00.
- Compliance period was 180 days, expiring April 24, 2023.
- On April 21, 2023, Nasdaq confirmed compliance after 10 consecutive business days of closing bid price at or above $1.00 from April 6-20.
- Matter is now closed; no further action needed on listing requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323002460/0001171843-23-002460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323002460/f8k_042423.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-002460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer